MORIMOTO Satoshi
   Department   School of Medicine(Tokyo Women's Medical University Hospital), School of Medicine
   Position   Associate Professor
Article types Review article
Language English
Peer review Peer reviewed
Presence of invitation Invited paper
Title Critical appraisal and pooled analysis of telmisartan alone or in combination with hydrochlorothiazide for achieving blood pressure goals.
Journal Formal name:Integrated blood pressure control
Abbreviation:Integr Blood Press Control
ISSN code:11787104/11787104
Domestic / ForeginForegin
Volume, Issue, Page 3,pp.73-9
Author and coauthor Morimoto Satoshi†*, Takahashi Nobuyuki, Morita Tatsuyori, Someya Kazunori, Toyoda Nagaoki, Iwasaka Toshiji
Authorship Lead author,Corresponding author
Publication date 2010
Summary Rigid control of blood pressure (BP) is essential to prevent cardiovascular disease. However, only about 40% of hypertensive patients undergoing pharmacological intervention with a single agent achieve their BP goals in contemporary clinical practice. Combined therapy using currently available agents is effective in maximizing treatment outcome, although it raises medical costs and decreases the drug compliance rate. To overcome such negative consequences, a combination tablet containing an angiotensin II receptor blocker (ARB) with a small dose of hydrochlorothiazide (HCTZ) is now available on the international market, including Japan. This article briefly describes the unique properties of telmisartan, a highly selective ARB for the angiotensin II type 1 receptor, including its long-acting characteristics and recent prospective multicenter randomized clinical trials, followed by a description of a newly-introduced combination tablet in Japan, which contains telmisartan and HCTZ. This article also reviews its safety and efficacy based on currently available evidence. Finally, evidence comparing telmisartan/HCTZ with other combination therapies is presented.
DOI 10.2147/ibpc.s9325
PMID 21949623